JP2018118936A5 - - Google Patents

Download PDF

Info

Publication number
JP2018118936A5
JP2018118936A5 JP2017012594A JP2017012594A JP2018118936A5 JP 2018118936 A5 JP2018118936 A5 JP 2018118936A5 JP 2017012594 A JP2017012594 A JP 2017012594A JP 2017012594 A JP2017012594 A JP 2017012594A JP 2018118936 A5 JP2018118936 A5 JP 2018118936A5
Authority
JP
Japan
Prior art keywords
polyethylene glycol
enteric
solid preparation
layer
granule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017012594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018118936A (ja
JP7064683B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2017012594A priority Critical patent/JP7064683B2/ja
Priority claimed from JP2017012594A external-priority patent/JP7064683B2/ja
Publication of JP2018118936A publication Critical patent/JP2018118936A/ja
Publication of JP2018118936A5 publication Critical patent/JP2018118936A5/ja
Application granted granted Critical
Publication of JP7064683B2 publication Critical patent/JP7064683B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017012594A 2017-01-27 2017-01-27 腸溶層破損防止用組成物 Active JP7064683B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017012594A JP7064683B2 (ja) 2017-01-27 2017-01-27 腸溶層破損防止用組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017012594A JP7064683B2 (ja) 2017-01-27 2017-01-27 腸溶層破損防止用組成物

Publications (3)

Publication Number Publication Date
JP2018118936A JP2018118936A (ja) 2018-08-02
JP2018118936A5 true JP2018118936A5 (enExample) 2020-03-05
JP7064683B2 JP7064683B2 (ja) 2022-05-11

Family

ID=63042993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017012594A Active JP7064683B2 (ja) 2017-01-27 2017-01-27 腸溶層破損防止用組成物

Country Status (1)

Country Link
JP (1) JP7064683B2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020055755A (ja) * 2018-09-28 2020-04-09 日本ケミファ株式会社 腸溶性製剤
JP7640453B2 (ja) * 2019-04-25 2025-03-05 富士製薬工業株式会社 医薬製剤およびその製造方法
JP2021046372A (ja) * 2019-09-19 2021-03-25 日医工株式会社 エソメプラゾール含有製剤
JPWO2021153525A1 (enExample) * 2020-01-27 2021-08-05
JP7583542B2 (ja) * 2020-07-16 2024-11-14 東和薬品株式会社 機能性薬効粒子およびその製造方法ならびに口腔内崩壊錠
CN114569579B (zh) * 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
JP7786701B2 (ja) * 2021-06-10 2025-12-16 富士化学工業株式会社 腸溶性の粒状物及びそれを含有する固形製剤
JP2023114904A (ja) * 2022-02-07 2023-08-18 沢井製薬株式会社 エソメプラゾール含有顆粒及びそれを含む口腔内崩壊錠

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1195500C (zh) * 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
EP1596838A2 (en) * 2003-02-11 2005-11-23 Torrent Pharmaceuticals Ltd Once a day orally administered pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
CN1263450C (zh) * 2005-01-20 2006-07-12 北京科信必成医药科技发展有限公司 奥美拉唑及其衍生物的口腔崩解片及其制备工艺
EP2138166A4 (en) * 2007-04-26 2012-11-21 Eisai R&D Man Co Ltd PROCESS FOR PRODUCING TABLETS
WO2008140459A1 (en) * 2007-05-16 2008-11-20 Fmc Corporation Solid form
EP2044932A1 (en) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Mechanical protective layer for solid dosage forms

Similar Documents

Publication Publication Date Title
JP2018118936A5 (enExample)
JP2021509912A5 (enExample)
JP2017105763A5 (enExample)
IL262581B1 (en) Production methods, preparations and medical applications of drugs containing cannabis for oral administration
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
JP2018064407A5 (enExample)
MX2017001540A (es) Tabletas de rucaparib de dosificacion elevada.
CL2013001793A1 (es) Comprimido de desintegracion oral de liberacion controlada que comprende i) granulos que contienen lanzoprazol y una capa de recubrimiento que comprende un copolimero y ii) granulos que comprenden lanzoprazol y una capa de recubrimiento que comprende un copolimero y un polimero, con granulos de tamaño medio de no mas de 500 µm.
EP3417861A4 (en) PHARMACEUTICAL COMPOSITION WITH JAK KINASEINHIBITOR OR PHARMACEUTICALALLY SALT OF IT
JP2017537928A5 (enExample)
JP2015005731A5 (ja) 酸化物半導体膜
TN2013000229A1 (en) Orally disintegrating tablet
JP2016510130A5 (enExample)
CL2018000246A1 (es) Tableta
CL2014002524A1 (es) Composicion farmaceutica que comprende un compuesto activo de formula 1, antagonista de ccr3, dos diluyentes, un aglutinante, un desintegrante y un lubricante; formas de dosificacion en capsula, comprimido o comprimido recubierto con pelicula.
CR20160192A (es) Formulación de farmaco de liberación retardada
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
JP2019046850A5 (enExample)
JP2016540019A5 (enExample)
WO2011140446A3 (en) Pharmaceutical formulations
JP2015510928A5 (enExample)
JP2016513680A5 (enExample)
CL2015003561A1 (es) Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular.
Utkewicz et al. Epistaxis complicated by rivaroxaban managed with topical tranexamic acid
CL2017003350A1 (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc